CyGenics’ Subsidiary Signs Distribution Agreement with CombiMatrix
News Dec 01, 2005
CyGenics Limited has announced that its wholly-owned subsidiary, Cell Sciences Ltd, has entered into a nonexclusive distribution agreement with CombiMatrix group of Acacia Research Corporation to distribute CombiMatrix products and services in Singapore.
Under the terms of the agreement, Cell Sciences will market and sell CustomArrays™, CatalogArrays™ and CustomArray Synthesizers, which are semiconductor-based tools for use in identifying and determining the roles of genes, and the recently introduced Influenza Research Microarray, to the Southeast Asian market.
"We are very pleased to have expanded our distribution network into Southeast Asia," said Michael Tognotti, Vice President of Sales and Marketing for CombiMatrix.
"I am confident that by joining forces with Cell Sciences, we can accelerate sales growth and enhance our collective market share."
"Cell Sciences has identified CombiMatrix’s platform technology to rapidly produce customizable arrays for applications in the areas of proteomics, genomics and nanotechnology," said Mr Steven Fang, Group CEO, CyGenics.
"This has a huge market potential in the Asia Pacific region and we look forward to a long and fruitful relationship."
Genetic Diversity Helps Protect Against DiseaseNews
Why do populations have genetic diversity when 'Survival of the Fittest' suggests that only one gene pool should thrive? It's a question that is hard to answer experimentally. A new study looking at evolutionary change in real time in tiny fungal parasites may provide a solution.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE